Dr. Matthew Taub, a board-certified physician specializing in internal medicine, hematology, and oncology, possesses more than 20 years of clinical experience. In addition to his work on several medical committees, Dr. Matthew Taub holds membership in the American Society of Clinical Oncology (ASCO).
For over a decade, ASCO has released Clinical Cancer Advances, an annual report detailing the year’s most significant advances in cancer treatment. The 2018 release brings focus to several Food and Drug Administration-approved therapies for their impact in the fight against cancer.
In 2017, the FDA approved pembrolizumab for use in patients with certain types of metastatic tumors. The immunotherapy drug is first in a line of tissue-agnostic therapies, treatments that work based on a tumor’s biomarkers, to be approved.
The report also chronicles improvements in targeted therapies for lung, breast, and bladder cancers and reviews the promising effects of radiotherapy and tumor-treating fields on aggressive forms of brain cancer.
Pembroke Pines, Florida-based physician Dr. Matthew Taub has more than two decades of experience treating blood-related disorders and cancers at Optimum Oncology Hematology Associates. At the clinic, Dr. Matthew Taub is part of a multidisciplinary staff that addresses common blood disorders such as anemia.
Anemia is a red blood cell disorder that affects more than 3 million Americans. In addition to a low hemoglobin count, anemia causes fatigue, headaches, and irregular heartbeats. The following risk factors are highly associated with anemia:
Limited Diet: Anemia can be triggered by a diet lacking in vitamin B12, iron, and folate. For this reason, people who eat restricted diets, including vegan and vegetarian, are especially susceptible.
Age: The likelihood of developing anemia due to iron deficiency increases after the age of 65. Additionally, women may experience low iron levels during pregnancy and childbirth, making anemia more common for women around childbearing age.
Associated Diagnosis: Anemia is also associated with other chronic illnesses, including cancer as well as diseases of the thyroid, liver, and kidneys. Autoimmune diseases such as rheumatoid arthritis have also been linked to a higher likelihood of anemia.
Compassionate physician Dr. Matthew Taub has been working in the hematology and oncology field for more than two decades. A physician at Optimum Oncology Hematology Associates in Florida, he has treated several benign and malignant disorders over the course of his career. Committed to remaining apprised of developments in his field, Dr. Matthew Taub attends numerous professional meetings during the year.
In December 2018, cancer researchers from Australia discovered a biomarker that can predict how well patients with metastatic prostate cancer will respond to chemotherapy. Known as the mGSTP1 (glutathione s transferase gene) biomarker, researchers discovered the presence of this gene in the blood of more than 80 percent of patients with metastatic castration-resistant prostate cancer (mCRPC). Following two cycles of chemotherapy using docetaxel, the biomarker was not found in 53 percent of cases. This decrease in mGSTP1 was also associated with better overall survival rates and slower progression of the disease.
Scientists discovered that mGSTP1 was a biomarker for prostate cancer more than two decades ago. However, the current study was the first phase 3 investigation of how patients with this gene responded to chemotherapy. Although more research is needed, scientists feel that the discovery of how mGSTP1 responds to chemotherapy will help physicians better customize treatment based on the genetic makeup of a patient’s cancer. It will also hopefully lead to the development of the first epigenetic biomarkers for prostate cancer.
Trained at New York Medical College and the now-dissolved University of Medicine and Dentistry of New Jersey, Dr. Matthew Taub is a board-certified oncologist based in Florida. Drawing on decades of experience, Dr. Matthew Taub provides evidence-based medical treatment in accordance with guidelines published by the National Cancer Committee Network for a wide range of cancers.
Until recently, no FDA-approved treatment existed for patients with newly-diagnosed CD30-expressing peripheral T-cell lymphomas (PTCLs). Now, the FDA recommends treating PTCLs using brentuximab vedotin injection in conjunction with chemotherapy. This conclusion was made within two weeks of submission to the agency due to the new Real-Time Oncology Review (RTOR) program. Intended to expedite the clinical availability of lifesaving treatments, the RTOR was just launched this past July.
The FDA looked at the ECHELON-2 clinical trial involving 452 patients with PTCLs when it made its decision. Patients in the trial received standard chemotherapy or chemotherapy with brentuximab vedotin injection. In the later arm of the study, patients experienced a median of 48 months of progression-free survival compared to 21 months for the control group with a P-value of 0.01.
Possessing more than two decades of professional experience, Dr. Matthew Taub is a board-certified oncologist who also trained in hematology. Dr. Matthew Taub treats patients through Everglades Oncology and Hematology in Miramar, Florida. Relying on evidence-based practices in oncology, he continually seeks out new information that can improve the patient experience, especially in relation to chemotherapy.
Researchers have recently found that a daily lactoferrin supplement may help mitigate some of the taste and smell abnormalities observed in patients who undergo chemotherapy. About 60 to 70 percent of patients experience these issues in relation to this treatment, but researchers have still not identified the underlying cause. Alleviating these symptoms could help generate more optimism among patients battling cancer.
The initial study, conducted at Virginia Polytechnic Institute (Virginia Tech), involved only 19 patients and 12 healthy controls. The researchers associated taste and smell abnormalities with high levels of salivary iron and the loss of certain salivary immune proteins. Lactoferrin supplementation was found to reduce salivary iron significantly while increasing immune proteins like annexin A1 and proteinase inhibitor. In addition, there was a significant reduction in the taste and smell abnormality score among patients undergoing chemotherapy, with a P-value of less than 0.001.
Dr. Matthew Taub treats patients with cancer as an oncologist at Everglades Oncology and Hematology in Florida. Emphasizing evidence-based care, Dr. Matthew Taub also has extensive experience as a practicing hematologist focused on blood-related diseases.
As reported in the Oncology Times, one promising area of treatment involves the use of immunotherapy to address hematologic malignancies. One type of immunotherapy, allogeneic hematopoietic stem cell transplantation (HCT), has been employed for decades and has proved invaluable in treating leukemia in patients who undergo stem cell transplantation.
Immunological responses are a critical factor when undertaking HCT stem cell grafts, as the body often mounts immune responses against the transplants. Individualizing the immunotherapy approach with the help of big data enables the graft-versus-leukemia effect without triggering graft-versus-host disease.
Another advancement in immunotherapy involves CAR T-cell therapy, which has been FDA approved since 2017 and is effective in treating acute lymphoblastic leukemia. The new approach involves reprogramming healthy cells in ways that direct them to destroy cancer cells.
After earning his medical degree from Ross University School of Medicine, Dr. Matthew Taub started a fellowship in oncology at St. Vincent’s Medical Center, where he was given the Best Fellow accolade. Since 2003, Dr. Matthew Taub has worked as a hematological oncology physician for Optimum Oncology Hematology Associates.
When a patient receives a cancer diagnosis, the next physician he or she will most likely see is a clinical oncologist. Clinical oncologists work with a cancer specialist team that often includes radiologists and specialized nurses. The clinical oncologist is responsible for assessing a patient’s prognosis and determining the most effective course of therapy.
Clinical oncologists are tasked with presenting the patient’s treatment options alongside realistic outcomes. This aspect of the job requires compassion, high levels of emotional intelligence, and a thorough knowledge of advances in systemic (whole-body) cancer therapies.
Many clinical oncologists are also site-specialists who concentrate on specific types of cancer. This can include pediatric cancers and colorectal cancer.